This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Subscribe To Our Newsletter & Stay Updated
